Form 8-K - Current report:
SEC Accession No. 0001683168-25-004421
Filing Date
2025-06-12
Accepted
2025-06-12 07:49:03
Documents
15
Period of Report
2025-06-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K phio_8k.htm   iXBRL 8-K 30682
2 OFFER LETTER phio_ex1001.htm EX-10.1 70077
3 PRESS RELEASE phio_ex9901.htm EX-99.1 12558
4 GRAPHIC image_001.jpg GRAPHIC 2205
  Complete submission text file 0001683168-25-004421.txt   307404

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE phio-20250606.xsd EX-101.SCH 3020
6 XBRL LABEL FILE phio-20250606_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE phio-20250606_pre.xml EX-101.PRE 22362
17 EXTRACTED XBRL INSTANCE DOCUMENT phio_8k_htm.xml XML 3700
Mailing Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752
Business Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 251041665
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)